Lars Petersen, Fujifilm Diosynth CEO
November 9, 2023 12:33 PM ESTUpdated November 10, 10:12 AM
Manufacturing

Com­mer­cial-stage man­u­fac­tur­ing key for CD­MOs as biotech fund­ing pull­back con­tin­ues, Fu­ji­film Diosynth CEO says

Anna Brown

News Reporter

On the back of re­duced fund­ing in ear­ly clin­i­cal-stage as­sets, CD­MOs need to strength­en their com­mer­cial, large-scale man­u­fac­tur­ing ca­pa­bil­i­ties for 2024 in what looks like …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times